Prostate cancer screening and ethical use of limited resources

New Zealand Medical Journal

Volumn 126, Issue 1385, 2013, Pages 92-94

  Ragupathy, Rajan ^a   Menkes, David B ^b  

^a WAIKATO DISTRICT HEALTH BOARD   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

COST BENEFIT ANALYSIS; HEALTH CARE UTILIZATION; HUMAN; LETTER; PHARMACOECONOMICS; PROSTATE CANCER; QUALITY OF LIFE; RISK FACTOR;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84887170375     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Gray B. Prostate cancer screening in New Zealand. N Z Med J. 27 Sept 2013;126(1383):94. http://journal.nzma.org.nz/journal/126-1383/5858/
2. Zohrab P. Doctors discussing PSA screening with their male patients. N Z Med J. 27 Sept 2013;126 (1383):95-96. http://journal.nzma.org.nz/journal/126-1383/5857/
3. Virginia A. Moyer, on behalf of the U.S. Preventive Services Task Force; Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Jul;157(2):120-134. doi: 10.7326/0003-4819-157-2-201207170-00459.
4. Monasterio E. The sickness of the USA model of healthcare-is it a contagious disease? N Z Med J. 27 Sept 2013;126 (1383):91-92. http://journal.nzma.org.nz/journal/126-1383/5856/
5. Gotzsche P. Commentary: medicalisation of risk factors. BMJ 2002;324:8861. http://www.bmj.com/content/324/7342/886.1
6. Martin AJ, Lord SJ, Verry HE, et al. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Med J Aust 3 Jun 2013;198 (10):546-50
7. Ragupathy, Y. (2013). New Zealanders' access to licensed and subsidised medicines compared with a nationwide single payer system in each of Australia, the United Kingdom and the United States (Doctoral dissertation, University of Otago).
8. Ragupathy R, Aaltonen K, Tordoff J, et al. A 3-dimensional view of access to licensed and subsidized medicines under single payer systems in the United States, United Kingdom, Australia and New Zealand. Pharmacoeconomics. 2012;30(11):1051-65
9. Cumming J, Mays N, Daubé J. Analysis: how New Zealand has contained expenditure on drugs. BMJ. 2010;340:c2441. http://www.bmj.com/content/340/bmj.c2441
10. Malone DC. The role of pharmacoeconomic modelling in evidence-based and value-based formulary guidelines. J Manag Care Pharm 2005 May;11 (2 Suppl) S7-10.